Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1 | Zendy

Éric Dailly | Zendy; Clotilde Allavena | Zendy; Matthieu Grégoire | Zendy; Véronique Reliquet | Zendy; Régis Bouquié | Zendy; Éric Billaud | Zendy; Hélène Hernando | Zendy; Sabelline Bouchez | Zendy; Guillaume Deslandes | Zendy; Nolwenn Hall | Zendy; Pascale Jolliet | Zendy; François Raffi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1

Author(s) -

Éric Dailly,

Clotilde Allavena,

Matthieu Grégoire,

Véronique Reliquet,

Régis Bouquié,

Éric Billaud,

Hélène Hernando,

Sabelline Bouchez,

Guillaume Deslandes,

Nolwenn Hall,

Pascale Jolliet,

François Raffi

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv245

Subject(s) - dolutegravir , nevirapine , pharmacokinetics , medicine , pharmacology , discontinuation , lamivudine , abacavir , cmax , dosing , regimen , virology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , virus , hepatitis b virus

The metabolic pathways of dolutegravir and nevirapine suggest a potential pharmacokinetic interaction between these drugs. The objective of this study was to investigate the influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research